Hervolution Therapeutics

Biotech & Life Sciences · Copenhagen, Denmark · Founded 2011

Immunotherapies targeting dark genome HERV antigens. MoreLess

Operator of a biotechnology company intended to treat cancer by targeting tumor viruses within the human genome. The company offers broad and curative cancer therapy in combination with immune checkpoint inhibitors, enabling medical researchers to easily find treatment for cancer using adaptive immune therapy.

Valuation $0–100M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

Hervolution Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2011
Headquarters: Copenhagen, Denmark
Employees: 35
Open positions: None listed
Dealroom signal: 84.0

Website ↗LinkedIn ↗X ↗

client focusb2bsub industryBioTechnologyindustryHealthsectorBiotechnologysectorOncologysectorDNAsectorGenetics and genomicssectorSpinoutsectorEICsectorBiotech and PharmasectorEIC FundsectorNordic Rising Star 2022sectorHorizon EuropesectorDT and LS

Valuation & funding

Hervolution Therapeutics funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2024	$12M	$47M	Serum Institute of India · EIC Fund	↗
SEED✓Equity / VC	May 2023	$6.6M	$26M	EIC Fund	↗
EARLY VC✓Equity / VC	Jun 2021	$0	—	EIC Fund	—
GRANT✓Other financing	Jun 2021	$2.5M	—	European Innovation Council	—
GRANT✓Other financing	Jul 2018	$220K	—	Undisclosed	—
SPINOUT✓Other financing	Oct 2011			University of Copenhagen	↗

Showing 6 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

Year	Profit	Margin	R&D
2026	−$1.3M	—	$0
2025	−$1.3M	—	$0
2024	−$1.3M	—	$0
2023			$0
2022
2021
2020

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Hervolution Therapeutics website traffic

Latest recorded traffic for Hervolution Therapeutics is 290 monthly website visits, down 27.5% over the last three months. Hervolution Therapeutics's team grew 25% over the past year.

Latest monthly visits290 3-month web change-27.5% 1-year team growth+25%

Monthly website visits66 observations · Dec 2018–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Hervolution Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational	22	$29M	$88M
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
IPIndex PharmaceuticalsDeveloping drugs to treat inflammatory bowel disease that can help patients return to a normal life	Solna kommun, Sweden	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
ABArthex BiotechFocused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs	Paterna, Spain	Operational
NPNETRIS PharmaMonoclonal antibodies overcoming cancer therapy resistance.	Lyon, France	Operational
OPOphiomicsOphiomics develops bioinformatics/genomics-based diagnostic products and services for liver cancer diagnosis, prognosis and follow-up.	Lisbon, Portugal	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Hervolution Therapeutics's talent

Book a demo to see the people

Team profiled 9 named & role-tagged

Founders /100 quality score

Key operators 4 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

9 investors on Hervolution Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage

European Innovation Council

Series A 2 investors entered at this stage

EIC Fund

Serum Institute of India

Other known 6 additional known investors

University of Copenhagen

Morten E. Wulff

Nicolaj Højer Nielsen

Peter Elbek

SeedFolio

Thor Angelo

Global footprint

Where Hervolution Therapeutics has talent and traffic

Workforce by country

6 countries with
team presence

🇩🇰 Denmark76.7%

🇨🇭 Switzerland6.7%

🇺🇸 United States6.7%

🏳️ Andorra3.3%

🇦🇺 Australia3.3%

Top 5 of 6 shown

In the news

Latest news about Hervolution Therapeutics

Recent press, funding announcements, and product moves mentioning Hervolution Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Hervolution Therapeutics

An AI-synthesized read of the highest-engagement posts about Hervolution Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hervolution Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.